13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • GO40558

    Acronym: 

    GO40558

    ACTRN/NCT /ethics: 

    NCT03815058

    Scientific title: 

    A study to evaluate the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase II Tumour Stream Melanoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2019-01-08
    Molecular Target Anticipated End Date 2022-09-01
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Melanoma
    Cancer Stage
    Anticipated Start Date 2019-01-08
    Anticipated End Date 2022-09-01

    Trial Summary

    This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

    Lay Summary

    A study to evaluate the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.

    Sponsor / Cooperative group

    Genentech Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6140 R Roberts-Thomson Recruiting